← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Pdx Pharmaceuticals, Inc.
Portland, OR
$10,653,039
Total funding
8
Grants
Funding over time
peak $2.3M · FY2012–25$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,653,039 · 8
By mechanism
R44$8,578,298 · 4
N43$1,200,000 · 1
R43$325,000 · 1
R41$299,741 · 1
SB1$250,000 · 1
Investigators at Pdx Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response$1,898,361
R44 · FY2021 · CA
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$1,288,251
R44 · FY2025 · CA
Novel siRNA-nanoparticle Platform for Treating Drug-Resistant HER2 Positive Breas$1,000,000
N43 · FY2014 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$932,751
R44 · FY2023 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$932,751
R44 · FY2024 · CA
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$914,249
R44 · FY2024 · CA
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$745,151
R44 · FY2018 · CA
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$513,354
R44 · FY2019 · CA
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$400,000
R44 · FY2023 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$378,030
R44 · FY2021 · CA
Development of topical formulation of siRNA-nanoparticle for treating skin diseases$325,000
R43 · FY2017 · TR
Iron functionalized silica as oral phosphate binder to treat hyperphosphatemia$299,741
R41 · FY2012 · DK
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$233,858
R44 · FY2019 · CA
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$224,965
R44 · FY2017 · CA
Novel siRNA-nanoparticle Platform for Treating Drug-Resistant HER2 Positive Breas$200,000
N43 · FY2013 · CA
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment$160,652
SB1 · FY2024 · CA
In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response$101,639
R44 · FY2022 · CA
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment$89,348
SB1 · FY2025 · CA
Supplement grant for R44CA217534: Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$14,938
R44 · FY2019 · CA